Annovis Bio, Inc.

ANVS
$1.84 (- $0.12 - 5.90%)
Last updated: 2026-07-10 15:09 UTC
ANVS Metrics
Exchange
🇺🇸 NYSE XNYS
New York Stock Exchange, Inc.United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS03615A1088
CUSIP03615A108
Market Price1.83
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-1.43
Market Cap$94.9M
Book Value0.65
Price to Book5.491
Beta1.49
52w High5.6
52w Low1.11
Next Earnings DateN/A

Annovis Bio, Inc. trades under ticker ANVS on NYSE as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US03615A1088, CUSIP 03615A108.

About the Company
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Price History